• Jolyon P Mitchell.
• Trudell Medical International, London, Ontario, Canada. jmitchell@trudellmed.com
• J Aerosol Med Pulm Drug Deliv. 2008 Mar 1;21(1):97-112.

AbstractThe laboratory evaluation of inhalers with facemasks for patient interface is so complex that testing without a facemask is generally undertaken, a practice that has been advocated in one standard. However, the facemask itself can profoundly influence medication delivery. A systematic review of the literature was undertaken to establish the development history of face models for the evaluation of facemasks used with inhalers and accessories. Initial attempts to simulate the facemask-face boundary employed a circular, firm rubber flange plate upon which the facemask was located. However, such models did not represent dead volume accurately, which is particularly important when assessing infant use. Subsequent developments included the creation of more realistic facial features, enabling the aerosol leaving the inhaler to be quantified at the facemask. In one instance (SAINT model), an anatomically correct nasopharyngeal cavity has been combined with a model face, enabling assessment of medication delivery to be extended to the lower respiratory tract. However, it is necessary either to apply sealants or to compress the facemask beyond normal to eliminate leakage with the rigid facial structure that is incomplete above the bridge of the nose. An oral-breathing infant full-face model (ADAM) intended to be used to quantify emitted mass at the patient interface incorporates flexible facial features to overcome this limitation. There is a need to extend the flexible face approach to other models that may be developed in the future for testing facemasks, whether or not they incorporate anatomically correct realizations of the upper respiratory tract.

20 keywords...

hide…